Invent, develop, and manufacture protein therapeutics

Akston Biosciences Corporation specializes in bringing protein therapeutics through the major phases of development, faster, more cost-effectively, and with a higher likelihood of success. We invent novel therapeutics using our Ambifect™ Fc-fusion platform. We develop and manufacture our therapeutics in our Animal Health protein manufacturing facility.

Here’s how we do it:

 

Owning the key development and manufacturing infrastructure

Akston designed and built a multi-kilogram-scale GMP biologics factory dedicated to Animal Health, with full Process Development and Quality Control capabilities, all under a state-of-the-art Quality Management System.

Using a common platform for all candidates

Each of our products is derived from the Ambifect™ Fc-fusion protein platform, leveraging common manufacturing and analytical processes to speed development and reduce regulatory risk.

Building deep partnerships

Akston licenses its candidates to go-to-market partners and also maintains close involvement with those partners in the product development process.

Company History

Akston was founded in 2011 by the team from SmartCells, Inc. that developed SmartInsulin and sold it to Merck & Co. in one of the largest preclinical pharmaceutical acquisitions in history.

In our first decade, Akston developed a strong pipeline, built and commissioned its GMP manufacturing and laboratory space, and assembled a vibrant team working to develop innovative therapeutics that improve lives.

Our first Ambifect™ platform candidate was developed in 2015, followed by our first veterinary candidates two years later.

In 2019, we signed a licensing agreement with Decha Pharmaceuticals and began building our new GMP biologics manufacturing facility.

In our second decade, Akston is focused on Companion Animal Health. We partner with Animal Health companies to take our companion animal therapeutics to market.

Akston also develops the human versions of our animal health candidates. These Human Health candidates are licensed to companies to advance their development.

In 2023, we created two subsidiaries: Vakston for human vaccine candidates and Diamune, Inc. for human diabetes candidates.

Akston Biosciences is an innovative company inventing, developing, and manufacturing protein therapeutics for companion animal health and quality-of-life.